Latancom (Timolol Maleate, Latanoprost)

• Latancom is an ophthalmic combination that treats conditions associated with elevated intra‑ocular pressure.
• Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage.
• Ocular hypertension: lowers pressure to prevent progression to glaucoma.
• Secondary open‑angle glaucoma: provides additional IOP reduction when monotherapy is insufficient.

• Timolol maleate non‑selectively blocks beta‑adrenergic receptors in the ciliary body, decreasing aqueous humor production. Latanoprost, a prostaglandin F2α analog, binds FP receptors to remodel the extracellular matrix, enhancing uveoscleral outflow. The dual action results in a synergistic reduction of intra‑ocular pressure.

Latancom may cause ocular and systemic reactions.

Common Side Effects

• Eye irritation or burning sensation
• Blurred vision shortly after instillation
• Conjunctival hyperemia (red eye)
• Dry eye or foreign‑body sensation
• Increased eyelash length and pigmentation
• Periocular skin darkening

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angio‑edema)
• Persistent eye pain or inflammation
• Sudden loss of vision
• Irregular pupil dilation or iris pigmentation changes
• Corneal edema or ulceration
• Systemic bradycardia or hypotension

Before prescribing Latancom, clinicians should consider patient‑specific factors and monitor for adverse events.

• Cardiovascular assessment: avoid in patients with severe bradycardia, heart block, or uncontrolled asthma/COPD.
• Ocular history: contraindicated in active intra‑ocular inflammation or infection.
• Allergy screening: do not use if hypersensitivity to timolol, latanoprost, or any excipients is known.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Monitoring: check intra‑ocular pressure regularly to assess therapeutic response.
• Store at room temperature: keep in original container, protect from light and moisture.

Latancom can interact with systemic and ocular agents, altering efficacy or safety.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers (e.g., propranolol): additive bradycardia or hypotension.
• Other prostaglandin analog eye drops: increased risk of ocular hyperemia and pigmentation changes.
• Sympathomimetic agents (e.g., epinephrine eye drops): may diminish IOP‑lowering effect.

Moderate Interactions (Monitor Closely)

• Topical anesthetics: may increase corneal toxicity when used together.
• Anticholinergic eye drops: possible alteration of pupil dynamics.
• Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive IOP reduction, monitor pressure closely.